ArchiveSCV
the-signal.com. The Santa Clarita Valley Signal. Back to the collection.

· archive.signalscv.com, Wayback capture

FDA decision regarding MannKind delayed

MannKind Corp. of Santa Clarita announced Monday that the U.S. Food and Drug Administration has extended by three months the review period of its ultra-rapid-acting diabetes treatment.

Review of Afrezza, a powder inhaled through a device the size of a whistle, was pushed back to July 15 by the FDA.

Inhaling the powder delivers the insulin treatment to the bloodstream within 12 to 15 minutes, compared to 90-150 minutes required for insulin injections.

Just last week an advisory panel to the FDA recommended approval of Afrezza, saying the biomedical company had clearly demonstrated its effectiveness.

But some members of the panel expressed concerns about possible side effects, including the affect the drug would have on the lungs.

Originally, the FDA decision had been expected around April 15.

← Back to 2014

About this record

How it was held, read and classified

Record details

Morris ID
117708
System
Morris section CMS (/section/…/article/… and /archives/…)
Reading copy
archive.signalscv.com
Chosen by: only copy held. On this copy: words 127 (e-mail addresses counted as one token); reader comments 0 (counted, not reproduced here); images 0.
Extracted by
section_cms:articlebody_span
signal-extract/0.15 (2026-11-16)

Other copies

Held
None. The holding has this article from one host only.

How it was classified

Label
clearly-local
Judgment
A machine’s (recorded as machine), kept as one so it can be revisited.
Classifier
signal-localclass/0.7 (2026-11-12)
Local signals
  • page:ad_target_section_36
  • byline:staff_marker [Signal Staff]
  • text:valley_names [1 distinct/1 mentions: Santa Clarita]
National signals
none fired
Scores
local 7, national 0